MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
MannKind (Nasdaq: MNKD) said it will release its fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026.
Rhea-AI Summary
MannKind (Nasdaq: MNKD) said it will release its fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. A live webcast reviewing results and providing a business update will begin at 9:00 a.m. ET.
The webcast will be accessible via MannKind's investor website link and a replay will be available within 24 hours and remain accessible for about 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MNKD
In the Feb 18 session, MNKD declined 1.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- February 26, 2026
- Scheduled Q4 and full-year 2025 results release
- Webcast time
- 9:00 a.m. Eastern Time
- Start time for earnings and business update webcast
- Replay availability
- Within 24 hours
- Earnings call replay posting after webcast
- Replay duration
- Approximately 90 days
- Time replay remains accessible on investor website
Historical Context
-
First patient enrolled in INHALE-1ST pediatric Afrezza study with PDUFA pending.
-
FDA approved updated Afrezza label with dosing conversion guidance for switches.
-
Business update highlighting record Q4 revenue and 2026 growth drivers.
-
FUROSCIX pediatric approval and new patents with extended IP and PDUFA date.
-
FDA accepted FUROSCIX ReadyFlow sNDA with supportive PK and bioavailability data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.